AARTIPHARM
Aarti Pharmalabs
Each stock's 10,000-path forecast, rendered as light.
Aarti Pharmalabs (AARTIPHARM) Stock Analysis & Case Study
Is AARTIPHARM a good buy? The data-driven verdict.
on the numbers it mixed signals, a Downstox Snapshot Score of 50/100.
On the numbers, Aarti Pharmalabs (AARTIPHARM) mixed signals, a Downstox Snapshot Score of 50/100, weighing a 46% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
AARTIPHARM share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of AARTIPHARM history (5%/yr drift, 44%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| AARTIPHARM 2027 | ₹378 | ₹662 | ₹1,161 | -4% |
| AARTIPHARM 2028 | ₹287 | ₹633 | ₹1,388 | -8% |
| AARTIPHARM 2029 | ₹231 | ₹604 | ₹1,598 | -13% |
| AARTIPHARM 2030 | ₹191 | ₹581 | ₹1,821 | -16% |
| AARTIPHARM 2031 | ₹164 | ₹565 | ₹1,995 | -18% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability AARTIPHARM goes up, or doubles?
The bull case for AARTIPHARM
- Aarti Pharmalabs is part of the NSE universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,598.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹231.
AARTIPHARM volatility & expected range, how bumpy is the ride?
Over the last 2.0 years AARTIPHARM compounded at 5%/year with annualized volatility of 44%. That volatility implies a 1-year 80% range of ₹378–₹1,161, the honest backbone behind any single price target.
AARTIPHARM price forecast, the full 60-month probability fan
AARTIPHARM price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds AARTIPHARM hits common targets within the simulated horizon?
Full multi-horizon detail on the AARTIPHARM price target & forecast page.
AARTIPHARM MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy AARTIPHARM with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 35.3% | 2.8× |
| ZerodhaCHEAPEST | 35.3% | 2.8× |
| DhanCHEAPEST | 35.3% | 2.8× |
Compare every broker on the AARTIPHARM MTF page.
AARTIPHARM vs peers,sector comparison
About Aarti Pharmalabs: sector, index & market-cap context
Aarti Pharmalabs (AARTIPHARM) is an NSE-listed company.
How the AARTIPHARM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Aarti Pharmalabs's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
AARTIPHARM analysis, FAQs
Is Aarti Pharmalabs (AARTIPHARM) a good buy?
On the numbers, Aarti Pharmalabs (AARTIPHARM) mixed signals, a Downstox Snapshot Score of 50/100, weighing a 46% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is AARTIPHARM overvalued or undervalued?
Valuation ratios for AARTIPHARM are tracked live on Downstox.
What is the AARTIPHARM share price target for 2031?
AARTIPHARM's probability-weighted 2031 median target is ₹565, with an 80% range of ₹164–₹1,995 (10,000-path Monte-Carlo).
What is the probability AARTIPHARM doubles in 5 years?
The modelled probability of AARTIPHARM reaching ₹1,384 (2×) within 5 years is 18%.
What is the bull case for AARTIPHARM?
Aarti Pharmalabs is part of the NSE universe with live, tracked fundamentals on Downstox.
What are the risks in AARTIPHARM?
No model or past record guarantees future returns, treat this as one input, not a decision.